Fig. 3: Comparative analysis of tumor-infiltrating immune cells across four molecular subtypes of breast cancer (BC).

A No significant difference in the prognosis was observed among the four molecular subtypes of BC. B Foxp3⁺ regulatory T cells are more prevalent in Her-2 positive and TNBC than in other subtypes (LumA vs LumB, P = 0.001; LumA vs TNBC, P = 0.009). D TNBC shows a significantly different distribution for several immune cell combinations compared to other subtypes: CD68⁺LAG3⁺ (TNBC vs LumB, P = 0.012; TNBC vs Her-2, P = 0.0007), CD68⁺PD-L1⁺ (TNBC vs LumA, P = 0.001; TNBC vs LumB, P = 0.001; TNBC vs Her-2, P = 0.002), FOXP3⁺LAG3⁺ (TNBC vs LumA, P = 0.002; TNBC vs LumB, P = 0.001; TNBC vs Her-2, P = 0.000), FOXP3⁺PD-L1⁺ (TNBC vs LumA, P = 0.042; TNBC vs Her-2, P = 0.034), LAG3⁺PD-L1⁺ (LumA vs TNBC, P = 0.000; TNBC vs LumB, P = 0.000; TNBC vs Her-2, P = 0.000), LAG3⁺PANCK⁺ (TNBC vs Her-2, P = 0.006). PD-L1⁺PANCK⁺ (TNBC vs LumB, P = 0.0008). C, E The distribution of CD68⁺, LAG3⁺, PD-L1⁺, TIM3⁺, CD4⁺, CD8⁺, PD1⁺, CD3⁺, CD4⁺PD1⁺, CD4⁺TIM3⁺, CD8⁺PD1⁺, CD8⁺TIM3⁺, TIM3⁺PANCK⁺, and PD1⁺TIM3⁺ immune cells was not significantly different across the four molecular subtypes of BC. TNBC triple-negative breast cancer, LumA luminal A, LumB luminal B, Her-2 human epidermal growth factor receptor 2.